Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

61. Meta-Analysis of Usefulness of Psyllium Fiber as Adjuvant Antilipid Therapy to Enhance Cholesterol Lowering Efficacy of Statins (Abstract)

Meta-Analysis of Usefulness of Psyllium Fiber as Adjuvant Antilipid Therapy to Enhance Cholesterol Lowering Efficacy of Statins Statins are usually well-tolerated drugs with a clear dose-dependent efficacy. However, manifestation of statin's side effects also bears a direct relation to higher doses necessary to achieve high impact cholesterol-lowering effects. Nevertheless, the reliance on statin efficacy alone has often left dietary intervention underutilized even though studies have shown (...) a reduction in serum cholesterol levels when dietary fiber intake is increased. In this meta-analysis, we investigated whether the concomitant use of psyllium, a gel-forming viscous soluble fiber, would cause further overall cholesterol lowering in subjects already receiving statins. A systematic review of the medical literature was performed and identified three randomized, controlled clinical studies that evaluated the cholesterol lowering efficacy of statins when given concomitantly with psyllium

2018 EvidenceUpdates

62. Statin

Statin Top results for statin - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for statin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

63. Association of statin use with spontaneous intracerebral hemorrhage: A cohort study (Abstract)

Association of statin use with spontaneous intracerebral hemorrhage: A cohort study To examine the association between statin exposure in a dose-dependent manner and intracerebral hemorrhage (ICH) in a large nationwide study.The computerized database of the largest health care provider in Israel was used to identify diagnosed ICH among new users of statins, who started statin treatment between 2005 and 2010. We assessed a dose-response relationship between ICH and statins, using the average (...) and robust among highly persistent statin users and after controlling for the change in cholesterol level.This study confirms that the risk of ICH decreases with increasing cholesterol levels, but suggests that statin use might be associated with decreased risk of ICH.© 2018 American Academy of Neurology.

2018 EvidenceUpdates

64. Making Sense of the Statin-Prostate Cancer Relationship: Is It Time for a Randomized Controlled Trial? (Abstract)

Making Sense of the Statin-Prostate Cancer Relationship: Is It Time for a Randomized Controlled Trial? 28753767 2018 07 10 2018 12 02 2405-4569 3 2-3 2017 04 European urology focus Eur Urol Focus Making Sense of the Statin-Prostate Cancer Relationship: Is It Time for a Randomized Controlled Trial? 221-222 S2405-4569(16)30068-2 10.1016/j.euf.2016.06.008 Hamilton Robert J RJ Division of Urology, Departments of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network

2018 European urology focus Controlled trial quality: uncertain

65. Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use

Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use Prescrire IN ENGLISH - Spotlight ''Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use '', 1 July 2018 {1} {1} {1} | | > > > Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use FEATURED REVIEW Given its weak efficacy and sometimes serious adverse effects, the harm-benefit balance of statin therapy in primary cardiovascular prevention is uncertain and close to neutral. Much else can be done to reduce

2018 Prescrire

66. Association of a Family History of Coronary Heart Disease With Initiation of Statin Therapy in Individuals at Intermediate Risk: Post Hoc Analysis of a Randomized Clinical Trial. Full Text available with Trip Pro

Association of a Family History of Coronary Heart Disease With Initiation of Statin Therapy in Individuals at Intermediate Risk: Post Hoc Analysis of a Randomized Clinical Trial. 27438122 2018 06 26 2018 06 26 2380-6591 1 3 2016 06 01 JAMA cardiology JAMA Cardiol Association of a Family History of Coronary Heart Disease With Initiation of Statin Therapy in Individuals at Intermediate Risk: Post Hoc Analysis of a Randomized Clinical Trial. 364-6 10.1001/jamacardio.2016.0227 Safarova Maya S MS

2018 JAMA cardiology Controlled trial quality: uncertain

67. Do statins prevent dementia?

Do statins prevent dementia? Do statins prevent dementia? – Morsels of Evidence \t\t\t\r\n\t\t\t \t\t\t\r\n\t\t\t Like this: Like Loading... ","author":{"@type":"Person","name":"Michael Tam"},"image":["https:\/\/evidencebasedmedicine.com.au\/wp-content\/uploads\/2018\/06\/mo-june2018-pp54-55.png"]} Toggle search form Toggle navigation Evidence-based medicine for general practitioners Jun 25 2018 Do statins prevent dementia? By in , , , , Journal reference: McGuinness B, Craig D, Bullock R (...) , Passmore P. Statins for the prevention of dementia. Cochrane database of systematic reviews 2016 Jan 4(1):CD003160 Link: Published: January 2016 Evidence cookie says… Statins should not be used as a prophylaxis against dementia, as the only indication the limited evidence from high quality randomised trials suggests no effect there is some ambiguity as observational data has tended to suggest a protective effect The article was published in the June 2018 issue of Medical Observer , under the title

2018 Morsels of Evidence

68. Do statins prevent dementia?

Do statins prevent dementia? Do statins prevent dementia? – Morsels of Evidence \t\t\t\r\n\t\t\t \t\t\t\r\n\t\t\t Like this: Like Loading... ","author":{"@type":"Person","name":"Michael Tam"},"image":["https:\/\/evidencebasedmedicine.com.au\/wp-content\/uploads\/2018\/06\/mo-june2018-pp54-55.png"]} Toggle search form Toggle navigation Evidence-based medicine for general practitioners Jun 25 2018 Do statins prevent dementia? By in , , , , Journal reference: McGuinness B, Craig D, Bullock R (...) , Passmore P. Statins for the prevention of dementia. Cochrane database of systematic reviews 2016 Jan 4(1):CD003160 Link: Published: January 2016 Evidence cookie says… Statins should not be used as a prophylaxis against dementia, as the only indication the limited evidence from high quality randomised trials suggests no effect there is some ambiguity as observational data has tended to suggest a protective effect The article was published in the June 2018 issue of Medical Observer , under the title

2018 Morsels of Evidence

69. Do statins prevent dementia?

Do statins prevent dementia? Do statins prevent dementia? – Morsels of Evidence \t\t\t\r\n\t\t\t \t\t\t\r\n\t\t\t Share this: Like this: Like Loading... ","author":{"@type":"Person","name":"Michael Tam"},"image":["https:\/\/evidencebasedmedicine.com.au\/wp-content\/uploads\/2018\/06\/mo-june2018-pp54-55.png"]} Toggle search form Toggle navigation Evidence-based medicine for general practitioners Jun 25 2018 Do statins prevent dementia? By in , , , , 25 June 2018 Journal reference: McGuinness B (...) , Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane database of systematic reviews 2016 Jan 4(1):CD003160 Link: Published: January 2016 Evidence cookie says… Statins should not be used as a prophylaxis against dementia, as the only indication the limited evidence from high quality randomised trials suggests no effect there is some ambiguity as observational data has tended to suggest a protective effect The article was published in the June 2018 issue of Medical Observer

2018 Morsels of Evidence

70. The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy Full Text available with Trip Pro

The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy Statins and/or PCSK9 inhibitors cause the regression of coronary atheroma and reduce clinical events. However, it currently remains unclear whether these drugs modulate coronary atheroma calcification in vivo. Coronary artery calcium (CAC) scores (Agatston Units, AUs) were estimated in 120 patients receiving coronary computed tomographic (...) angiography (CCTA) (63% males; median age 56 years). The CAC scores were compared among the three groups: (1) neither statin nor PCSK9 inhibitor therapy, (2) statin monotherapy, and (3) statin and PCSK9 inhibitor combination therapy in an unpaired cross-sectional study. Additionally, CCTA was performed twice at an interval in 15 patients undergoing statin monotherapy to compare the previous (baseline) and subsequent (follow-up) CAC scores in a paired longitudinal study. In addition, a PCSK9 inhibitor

2018 NPJ aging and mechanisms of disease

71. Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial Full Text available with Trip Pro

Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial To compare alirocumab, a proprotein convertase subtilisin-kexin type 9 inhibitor, with usual care (UC) in individuals with type 2 diabetes (T2DM) and mixed dyslipidaemia not optimally managed by maximally tolerated statins in the ODYSSEY DM-DYSLIPIDEMIA trial (NCT02642159).The UC options (no additional lipid-lowering (...) non-HDL cholesterol to a greater degree within each UC stratum at week 24. The incidence of treatment-emergent adverse events was 68.4% (alirocumab) and 66.4% (UC). No clinically meaningful effect on glycated haemoglobin, or change in number of glucose-lowering agents, was seen.In individuals with T2DM and mixed dyslipidaemia on maximally tolerated statin, alirocumab showed superiority to UC in non-HDL cholesterol reduction and was generally well tolerated.© 2018 The Authors. Diabetes, Obesity

2018 EvidenceUpdates

72. Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study Full Text available with Trip Pro

Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study Diabetes is associated with high risk of cardiovascular (CV) events, particularly in patients with dyslipidemia and diabetic complications. We investigated the incidence of CV events with intensive or standard lipid-lowering therapy in patients with hypercholesterolemia, diabetic retinopathy, and no history of coronary artery disease (treat (...) -to-target approach).In this multicenter, prospective, randomized, open-label, blinded end point study, eligible patients were randomly assigned (1:1) to intensive statin therapy targeting LDL cholesterol (LDL-C) <70 mg/dL (n = 2,518) or standard statin therapy targeting LDL-C 100-120 mg/dL (n = 2,524).Mean follow-up was 37 ± 13 months. LDL-C at 36 months was 76.5 ± 21.6 mg/dL in the intensive group and 104.1 ± 22.1 mg/dL in the standard group (P < 0.001). The primary end point events occurred in 129

2018 EvidenceUpdates

73. Statins are of no benefit in acute respiratory distress syndrome

Statins are of no benefit in acute respiratory distress syndrome Statins are of no benefit in acute respiratory distress syndrome Discover Portal Discover Portal Statins are of no benefit in acute respiratory distress syndrome Published on 13 March 2018 doi: Giving statins to patients with acute respiratory distress syndrome made no difference to the number of days they spent on a ventilator. It also had no effect on mortality or the length of time spent in intensive care or in hospital (...) compared with placebo. In acute respiratory distress syndrome, the lungs become severely inflamed, fill with fluid (pulmonary oedema) and can no longer function. The person needs mechanical ventilation and is at high risk of multiple organ failure and mortality. This serious condition has high impact on both patients and NHS resources. Early studies had suggested statins may help to reverse the inflammatory process and could be a potential treatment to explore. This large, multicentre trial, funded

2018 NIHR Dissemination Centre

74. A statin drug during admission for heart surgery did not prevent an irregular heart beat

A statin drug during admission for heart surgery did not prevent an irregular heart beat A statin drug during admission for heart surgery did not prevent an irregular heart beat Discover Portal Discover Portal A statin drug during admission for heart surgery did not prevent an irregular heart beat Published on 14 July 2016 doi: The statin, rosuvastatin, taken by adults before and after heart surgery, did not prevent atrial fibrillation or heart muscle injury compared to placebo. Acute kidney (...) to reduce atrial fibrillation, nor heart muscle damage. It did, as expected, reduce “bad” cholesterol and C-reactive protein, a marker of inflammation, compared to the inactive placebo. Statins do have proven longer term benefits in reducing further damage to the coronary arteries and deaths from heart disease. Share your views on the research. Why was this study needed? Atrial fibrillation can occur in about 20% of people undergoing heart surgery and if not corrected is associated with poorer recovery

2018 NIHR Dissemination Centre

75. The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: a cohort and nested case-control study Full Text available with Trip Pro

The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: a cohort and nested case-control study To obtain evidence of the effects of metformin and statins on the incidence of ovarian cancer in women with type 2 diabetes (T2D).A retrospective cohort study and nested case-control study.The data were obtained from a diabetes database (FinDM) combining information from several nationwide registers.A cohort of 137 643 women over 40 years old and diagnosed (...) with T2D during 1996-2011 in Finland.In full cohort analysis Poisson regression was used to estimate the hazard ratios (HR) in relation to ever use of metformin, insulin other oral anti-diabetic medication or statins. In the nested case-control analysis 20 controls were matched to each case of ovarian cancer. Conditional logistic regression was used to estimate HRs in relation to medication use and cumulative use of different medications. The estimates were adjusted for age and duration

2018 EvidenceUpdates

76. Do Statins Induce or Protect from Acute Kidney Injury and Chronic Kidney Disease: An Update Review in 2018 Full Text available with Trip Pro

Do Statins Induce or Protect from Acute Kidney Injury and Chronic Kidney Disease: An Update Review in 2018 Statins essentially are cholesterol-lowering drugs that are extensively prescribed for primary and secondary prevention of cardiovascular disease. Compelling evidence suggests that the beneficial effects of statins may not only be due to its ability to control cholesterol levels but also due to a pleiotropic cholesterol-independent anti-inflammatory, antioxidant, endothelial-protective (...) and plaque-stabilizing activity. Along this line, statins may also exert acute and long-term effects on renal function. We present a narrative literature review that summarizes arguments in favor of or against the preventive and/or therapeutic use of statins in kidney-related diseases or complications. We also highlight the ongoing controversy regarding statin therapy in chronic and end-stage kidney disease.

2018 Journal of translational internal medicine

77. Lipid-lowering drugs (statins) and peripheral neuropathy Full Text available with Trip Pro

Lipid-lowering drugs (statins) and peripheral neuropathy Peripheral neuropathy is a disorder with often unknown causes. Some drugs, including statins, are proposed to be among the causes of peripheral neuropathy. This study aimed at evaluating this condition by electrodiagnostic study among patients who had received statins.This case-control study was conducted in Shiraz, Iran in 2015, and included 39 patients aged 35-55 who had received statins for at least 6 months, and 39 healthy matched (...) for one definition [2 abnormalities in 2 nerves (p=0.055)]. Regarding mean values of the features, significant differences were observed in two features: amplitude of the peroneal motor nerve (p=0.048) and amplitude of the sural sensory nerve (p=0.036).Since statins are widely used, awareness regarding their side-effects would lead to better treatment. Even though no significant differences were found between the groups regarding the occurrence of peripheral neuropathy, there were significant

2018 Electronic physician

78. Synergistic effects of blood pressure-lowering drugs and statins: systematic review and meta-analysis Full Text available with Trip Pro

Synergistic effects of blood pressure-lowering drugs and statins: systematic review and meta-analysis Synergistic effects of blood pressure-lowering drugs and statins are unknown, but are key to risk-based treatment decision strategies and fixed-combination polypills.We conducted a systematic literature review and meta-analysis to test the hypothesis that the combined relative effects of blood pressure-lowering drugs and statins on cardiovascular outcomes are multiplicative.Two persons (...) independently searched five data sources and hand-searched reference lists from earliest available to December 2017. We included factorial trials with at least two randomised interventions including one statin versus placebo factor and one blood pressure-lowering drug/more intense blood pressure-lowering regimen versus placebo/less intense regimen factor, and reported cardiovascular events or mortality as outcomes. We tested interactions as departures from additivity or multiplicativity using mixed-effects

2018 BMJ evidence-based medicine

79. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies Full Text available with Trip Pro

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies Lipid profiles are altered by active disease in patients with rheumatoid arthritis (RA) and may be further modified by treatment with Janus kinase inhibitors and other disease-modifying antirheumatic drugs.Lipid data were analysed from phase II and III studies of 4 mg (n=997) and 2 mg (n=479) oral baricitinib administered once daily in patients with moderate-to-severe active RA. Lipoprotein (...) particle size and number and GlycA were evaluated with nuclear magnetic resonance in one phase III study. The effect of statin therapy on lipid levels was evaluated in patients on statins at baseline and in patients who initiated statins during the study.Treatment with baricitinib was associated with increased levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides, but no significant change in LDL-C:HDL-C ratio. Lipid

2018 EvidenceUpdates

80. Comparison of Five Major Guidelines for Statin Use in Primary Prevention in a Contemporary General Population. (Abstract)

Comparison of Five Major Guidelines for Statin Use in Primary Prevention in a Contemporary General Population. Five major organizations recently published guidelines for using statins to prevent atherosclerotic cardiovascular disease (ASCVD): in 2013, the American College of Cardiology/American Heart Association (ACC/AHA); in 2014, the United Kingdom's National Institute for Health and Care Excellence (NICE); and in 2016, the Canadian Cardiovascular Society (CCS), the U.S. Preventive Services (...) Task Force (USPSTF), and the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS).To compare the utility of these guidelines for primary prevention of ASCVD.Observational study of actual ASCVD events during 10 years, followed by a modeling study to estimate the effectiveness of different guidelines.The Copenhagen General Population Study.45 750 Danish persons aged 40 to 75 years who did not use statins and did not have ASCVD at baseline.The number of participants eligible

2018 Annals of Internal Medicine